EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

[18F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study

Runjun Yang, Han Tang, Yunze Xie, Danjie Cai, Yibo He, Zhe Zheng, Yu Lin, Huaping Gao, Wenxin Tang, Yihan Yan, Lijie Tan, Hongcheng Shi iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025-03 · 52 (4) · 1422-1435

DOI: 10.1007/s00259-024-07051-8 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 02.01.2025. Verfasst von Runjun Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Innovative Medical Device Application Demonstration Program of Shanghai Municipal Commission of Economy and Informatization, Chinese National Key Clinical Specialty Program, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To investigate the predictive value of 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG) PET/CT for evaluating primary tumor (PT) and lymph node (LN) responses after neoadjuvant programmed death-ligand 1 (PD-L1) blockade monotherapy in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC). METHODS: In the single-arm phase 1b NATION-1907 trial (NCT04215471), 23 patients with LA-ESCC received two cycles of neoadjuvant PD-L1 blockade Adebrelimab followed by surgery. Among these, 18 patients underwent [18F]FDG PET/CT scans both before immunotherapy and prior to surgery. Standardized uptake value corrected for lean body mass (SUL)-derived parameters, including SULmax and SULpeak, were documented for PTs and LNs. Lesions > 1cm3 were segmented using thresholds of 41% and 50% of SULmax, respectively, following European Association of Nuclear Medicine (EANM) guidelines, with metabolic tumor volume (MTV) and total lesion glycolysis (TLG) calculated. Percentage changes of all metabolic parameters were also recorded. Residual viable tumor ≤ 33% were classified as well-responders, whereas residual viable tumor > 33% were classified as poor-responders based on histological evaluation. RESULTS: In the PT analysis, 10 patients were classified as PT well-responders and 8 as PT poor-responders. All post-treatment metabolic parameters, except MTV, were significantly lower in well-responders compared to poor-responders. The %ΔMTV, %ΔTLG were significantly higher in the poor-responder group (all P < 0.05). ROC curves indicated %ΔMTV41 exhibited optimum performance in predicting well-responders, with an AUC of 0.875 (cut-off: -31.01). Furthermore, %ΔMTV41 significantly predicted patients' recurrence-free survival (RFS) (P < 0.1). In the LN analysis, 7 LNs were classified as well-responders and 10 as poor-responders. Pre-treatment SULmax, SULpeak were significantly lower in poor-responders compared to well-responders. Post-treatment MTV50 and all percentage changes in parameters were significantly higher in the poor-responder group (all P < 0.05). Receiver operating characteristic curve (ROC) analysis indicated %ΔTLG50 had excellent predictive performance for well-responders, with an AUC of 1.000 (cut-off: -7.5). However, there was no significant correlation between the metabolic response evaluations for PTs and LNs. CONCLUSION: The metabolic parameters of [18F]FDG PET/CT, particularly %ΔMTV and %ΔTLG, could effectively predict well-responders among both PTs and LNs to neoadjuvant PD-L1 blockade monotherapy in LA-ESCC, which may facilitate personalized immunotherapy and serve as a stratification tool in future larger-scale studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsNeoadjuvant TherapyB7-H1 AntigenHumansMaleFemaleMiddle AgedAgedTreatment OutcomeAdult

Stichwörter der Autor:innen

Locally advanced esophageal squamous cell carcinomaPD-L1 blockade monotherapyPathological response[18F]FDG PET/CT

Substanzen

Fluorodeoxyglucose F18B7-H1 Antigen

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.
  • Shanghai Institute of Medical Imaging, Shanghai, 200032, China.
  • Nuclear Medicine Institute of Fudan University, Shanghai, 200032, China.
  • Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
  • Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.
  • Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Tan.lijie@zs-hospital.sh.cn.

ORCID-Profile: Hongcheng Shi

Förderung

  • Innovative Medical Device Application Demonstration Program of Shanghai Municipal Commission of Economy and Informatization
  • Chinese National Key Clinical Specialty Program
  • National Key Research and Development Program of China

Zitieren

APA

Yang, R., Tang, H., Xie, Y., Cai, D., He, Y., Zheng, Z., Lin, Y., Gao, H., Tang, W., Yan, Y., Tan, L., & Shi, H. (2025). [18F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study. European Journal of Nuclear Medicine and Molecular Imaging, 52(4), 1422-1435. https://doi.org/10.1007/s00259-024-07051-8

Vancouver

Yang R, Tang H, Xie Y, Cai D, He Y, Zheng Z, et al. [18F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(4):1422-1435. doi:10.1007/s00259-024-07051-8

BibTeX
@article{Yang2025,
  author = {Yang, Runjun and Tang, Han and Xie, Yunze and Cai, Danjie and He, Yibo and Zheng, Zhe and Lin, Yu and Gao, Huaping and Tang, Wenxin and Yan, Yihan and Tan, Lijie and Shi, Hongcheng},
  title = {[18F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {4},
  pages = {1422--1435},
  doi = {10.1007/s00259-024-07051-8}
}
Kostenlos starten →